Tiziana Life Sciences (US) (TLSA) has released an update.
Tiziana Life Sciences has announced promising study results for their intranasal anti-CD3 monoclonal antibody, foralumab, in treating progression independent of relapse (PIRA) in multiple sclerosis patients. The treatment showed potential in reducing microglial activation, a key factor in MS progression, with data presented at the American Academy of Neurology Annual Meeting. This breakthrough could represent a significant advancement for MS patients who currently lack effective disease-modifying therapies for PIRA.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
